AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02450682 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Description: Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
Study NCT02952456 — intervention group
Intervention type: OTHER
Intervention: interview with a psychologist
Description: interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
Study NCT03866200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 ml once per day for 90 days
Study NCT01916395 — intervention group
Intervention type: DRUG
Intervention: sumatriptan and Treximet
Description: sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
Study NCT01129752 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: there is no intervention for this study
Study NCT01346800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
Study NCT01346800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
Study NCT01453504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHAP
Description: Dexamethasone, Cytarabine, Cisplatin
Study NCT01453504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DHAP
Description: Dexamethasone, Cytarabine, Cisplatin
Study NCT01453504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study NCT00995371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MILD® (Minimally Invasive Lumbar Decompression)
Description: Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
Study NCT00995371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
Study NCT01904487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]flumazenil
Description: \[11C\]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
Study NCT01904487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiagabine
Description: Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
Study NCT02134886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT02134886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02134886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02134886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01665638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
Study NCT01665638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
Study NCT03275922 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ZNS
Description: Zolmitriptan Nasal Spray
Study NCT02342093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20EE+DRSP
Description: Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
Study NCT04133064 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pivot Breath Sensor
Description: The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
Study NCT05428020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indwelling foley catheter
Description: short-term indwelling catheter inserted in the operating room prior to surgery, removed upon arrival to the floor from post-anesthesia care unit (approx 2-3 hours after surgery).
Study NCT05428020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No foley catheter
Description: No foley catheter is placed for surgery
Study NCT04366791 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy
Description: Undergo low-dose radiation therapy
Study NCT02482844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pacemaker implantation
Study NCT02482844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: holter implantation
Study NCT02650583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive Enhancing Connections Program
Study NCT02650583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03569462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile WeChat intervention
Description: Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
Study NCT05088577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg
Description: Daily consumption of two whole eggs during 8 weeks
Study NCT03569462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
Study NCT01980888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablet administered orally twice daily
Study NCT01980888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
Study NCT01980888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
Study NCT01980888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
Study NCT05088577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Annatto-enriched egg
Description: Daily consumption of two whole eggs enriched with annatto during 8 weeks
Study NCT05088577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg whites - Control
Description: Daily consumption of two eggs whites during 8 weeks
Study NCT04156919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fooya!™
Description: fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
Study NCT04156919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WordSearch
Description: We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
Study NCT02443220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electric acupoint stimulation)
Description: transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group
Study NCT02443220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEAS
Description: transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group
Study NCT02443220 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS
Description: The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia
Study NCT02071303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 100mg will be given to 70 women before the procedure.
Study NCT03056599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple drug microinjection
Description: This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
Study NCT03056599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CIVO device
Description: Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
Study NCT03167567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presence of a medical clown during labor
Description: Presence of a medical clown during labor
Study NCT02821143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual palliative care
Description: Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
Study NCT02821143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Description: Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~* Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~* Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~* Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~* In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above.
Study NCT01258998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO
Study NCT01258998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03274999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear™ Application
Description: Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
Study NCT03726567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Roux-en-Y surgery
Study NCT03859830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line
Description: The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
Study NCT03859830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AK200 Ultra S, extracorporeal circulation conduct of blood purification
Description: The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
Study NCT00002931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.
Study NCT00002931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=7, daily X 3
Study NCT00002931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 20 mg/kg by 2 hours infusion daily X 3
Study NCT00002931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 3 gm/m2 IV over 30 minutes X 3 days
Study NCT00002931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 425 mg/m2 as 24 hour continuous infusion
Study NCT00002931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Given in two divided infusions on day -2 and day 0
Study NCT00002931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Two cycles of high dose chemotherapy followed by stem cell reinfusion
Study NCT03861988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg over 40 minutes, intravenous.
Study NCT03861988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (placebo)
Description: Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
Study NCT01106469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 25mg tablet once daily
Study NCT01106469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 250mg tablet once daily
Study NCT01106469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 1500mg once daily (with 250mg tablets)
Study NCT01106469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 100mg tablet once daily
Study NCT01106469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 1000mg once daily (with 250mg tablets)
Study NCT01106469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01106469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 500mg once daily (with 250mg tablets)
Study NCT03224598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution 40%
Description: A-101 Topical Solution 40%
Study NCT05252260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
Study NCT05252260 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diode Laser
Description: Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
Study NCT01665638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
Study NCT01665638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-peptide
Description: Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
Study NCT01980888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
Study NCT01980888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match idelalisib administered orally twice daily
Study NCT03949673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fasinumab
Description: Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study NCT03949673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study NCT03949673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac
Description: Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study NCT03949673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study NCT03949673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study NCT01144273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity.
Study NCT01144273 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus abdominis plane block
Description: This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity.
Study NCT04391140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position
Description: HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
Study NCT01999829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citrate of caffeine
Study NCT01999829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01583036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin Alone
Description: Single administration of digoxin 0.25mg
Study NCT01583036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin + Retigabine
Description: Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
Study NCT04152759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
Description: Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)
Study NCT04152759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
Description: Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)
Study NCT02625402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief interactive decision aid
Description: The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis